Infant Colic & the Gut Microbiome: Probiotics, Causes, and Relief

Overview

Infant colic is defined by the Wessel criteria as crying for more than three hours per day, for more than three days per week, for at least three weeks in an otherwise healthy infant. It typically begins around two to three weeks of age and resolves spontaneously by three to four months. While often dismissed as a self-limiting nuisance, colic places enormous stress on families and is associated with increased risk of postpartum depression, early breastfeeding cessation, and shaken baby syndrome.

For decades, the cause of infant colic remained elusive. Conventional explanations ranged from parental inexperience to simple "gas pain." However, a growing body of research has fundamentally reframed colic as a condition rooted in gut microbiome dysbiosis, intestinal inflammation, and the developing gut-brain axis.^[1] This microbiome-centered understanding has opened the door to targeted interventions -- most notably the probiotic Lactobacillus reuteri DSM 17938, which now carries the strongest evidence base of any probiotic for any pediatric condition.

Key Takeaways

• Colicky infants have measurably different gut microbiome compositions, with higher levels of gas-producing Proteobacteria and lower levels of beneficial Lactobacillus and Bifidobacterium species.^[2]
• Lactobacillus reuteri DSM 17938 is the best-studied probiotic for infant colic, with multiple RCTs showing significant reductions in crying time, particularly in breastfed infants.^[3]
• Breast milk acts as both a prebiotic and a probiotic, seeding the infant gut with beneficial bacteria and providing human milk oligosaccharides (HMOs) that selectively nourish protective species.^[4]
• Delivery mode, antibiotic exposure, and feeding method all shape the trajectory of early-life microbiome development and may influence colic risk.^[5]
• Gut inflammation is a measurable feature of colic, not merely a theoretical link -- colicky infants show elevated fecal calprotectin levels, a validated biomarker of intestinal inflammation.^[1]

The Microbiome Connection

Gut Dysbiosis in Colicky Infants

Research consistently demonstrates that infants with colic harbor a fundamentally different gut microbial community compared to non-colicky peers. A landmark study following infants from birth through three months found that colicky infants had significantly higher proportions of Proteobacteria -- a phylum that includes many gas-producing species like Escherichia coli and Klebsiella -- weeks before the onset of crying symptoms.^[2] This temporal relationship is critical: the microbiome changes precede colic onset, suggesting a causal role rather than a mere consequence.

Colicky infants also show reduced populations of Lactobacillus and Bifidobacterium species that would normally dominate the healthy breastfed infant gut. This imbalance leads to increased gas production, altered bile acid metabolism, and reduced production of anti-inflammatory short-chain fatty acids.

Intestinal Inflammation and the Gut-Brain Axis

Colic is not just about gas. Research has demonstrated that colicky infants exhibit genuine gut inflammation, with significantly elevated fecal calprotectin concentrations and increased levels of pro-inflammatory cytokines in their stool.^[1] This inflammation activates visceral pain pathways through the gut-brain axis, a bidirectional communication network between the enteric nervous system and the central nervous system.

In infants, the gut-brain axis is still maturing, which may make them particularly susceptible to pain signals originating from intestinal inflammation. The vagus nerve, which serves as the primary communication highway between the gut and brain, transmits these inflammatory signals as pain, contributing to the distress and inconsolable crying that defines colic.

Breast Milk as a Microbiome Architect

Human breast milk is far more than nutrition -- it is a sophisticated microbiome-shaping system. Each milliliter contains hundreds of thousands of bacteria, including Lactobacillus, Bifidobacterium, and Streptococcus species, which directly seed the infant gut. Research published in JAMA Pediatrics demonstrated that breast milk bacterial communities significantly shape the establishment and development of the infant gut microbiome, with approximately 27.7% of bacteria in the infant gut originating from breast milk during exclusive breastfeeding.^[4]

Beyond live bacteria, breast milk contains over 200 distinct human milk oligosaccharides (HMOs). These complex sugars are indigestible by the infant but serve as selective fuel for beneficial Bifidobacterium species, particularly B. longum subsp. infantis. Infants who receive breast milk therefore develop gut communities enriched in protective, anti-inflammatory species -- a pattern inversely associated with colic.

Delivery Mode and Early Colonization

The method of delivery represents the infant's first major microbial exposure. Vaginally delivered infants are colonized by maternal vaginal and intestinal bacteria, including Lactobacillus, Prevotella, and Bacteroides species. In contrast, cesarean-delivered infants are initially colonized primarily by skin and environmental microbes, including Staphylococcus, Corynebacterium, and Propionibacterium species.^[5]

This difference in founding communities has downstream consequences. Cesarean-delivered infants take longer to establish robust populations of Bifidobacterium and Bacteroides, and some studies have reported modestly higher colic rates in this group. While the microbiome differences narrow over the first year of life, the early window is precisely when colic occurs, making these initial colonization patterns clinically relevant.

Key Microorganisms

Lactobacillus reuteri DSM 17938

Role: Protective -- the single most studied probiotic strain for infant colic

Lactobacillus reuteri DSM 17938 is a gut commensal that produces the antimicrobial compound reuterin and modulates intestinal motility, pain perception, and immune responses. Originally isolated from a Peruvian mother's breast milk, this strain has been the subject of more than a dozen randomized controlled trials in infant colic. Its mechanisms of action include inhibiting pathogenic bacteria, reducing gut inflammation, modulating visceral pain signaling, and improving gastric motility.^[3]

Bifidobacterium longum subsp. infantis

Role: Protective -- the primary HMO-utilizing species in breastfed infants

B. infantis is uniquely equipped to metabolize human milk oligosaccharides, producing acetate and lactate that lower gut pH and inhibit the growth of pathogenic Proteobacteria. Colicky infants frequently show reduced Bifidobacterium populations, and restoring these communities is a key therapeutic target.

Proteobacteria (Escherichia, Klebsiella)

Role: Potentially harmful when overabundant in infants

Elevated levels of Proteobacteria are the most consistent microbial finding in colicky infants.^[2] These gram-negative bacteria produce lipopolysaccharide (LPS), a potent activator of the innate immune system, and generate gas through fermentation that may contribute to abdominal distension and discomfort.

Microbiome-Based Management Strategies

Lactobacillus reuteri DSM 17938 Supplementation

The evidence for L. reuteri DSM 17938 in breastfed colicky infants is remarkably strong. A pivotal randomized, double-blind, placebo-controlled trial demonstrated that infants receiving L. reuteri DSM 17938 (10^8 CFU daily) had significantly reduced crying time compared to placebo, with 95% of treated infants showing improvement versus 7% in the control group by day 21.^[3] A systematic review with network meta-analysis confirmed these findings, establishing L. reuteri DSM 17938 as the most effective probiotic intervention for infant colic.^[6]

However, evidence in formula-fed infants is less consistent. One large Australian trial found no significant benefit over placebo in a mixed-feeding population, suggesting that the breast milk environment may be important for optimal L. reuteri efficacy.^[7] A comprehensive meta-analysis of RCTs confirmed that probiotics -- particularly L. reuteri -- significantly reduce crying time and improve gut microbiota composition in colicky infants, while also reducing inflammatory markers.^[8]

Evidence Level: Strong (breastfed infants) / Moderate (formula-fed infants)

Breastfeeding Support and Optimization

Given the profound microbiome-shaping properties of breast milk, supporting continued breastfeeding is a foundational strategy for colic management. Exclusive breastfeeding promotes a Bifidobacterium-dominant gut community that resists colonization by gas-producing Proteobacteria.^[4] For mothers experiencing breastfeeding difficulties due to a colicky infant, lactation support may be particularly valuable as a microbiome intervention.

Evidence Level: Moderate (indirect microbiome evidence)

Maternal Dietary Modifications

In some colicky breastfed infants, maternal dietary proteins -- particularly cow's milk protein -- may pass through breast milk and trigger intestinal inflammation in sensitized infants. This overlaps with the developing field of infant food allergies. Elimination diets in the nursing mother, particularly removing dairy, have shown benefit in some trials, though the evidence is not universal. This approach may be most relevant when there is a family history of allergic conditions or eczema.

Evidence Level: Preliminary to Moderate

Prebiotic and Synbiotic Approaches

Emerging research explores whether prebiotics -- particularly galacto-oligosaccharides (GOS) and fructo-oligosaccharides (FOS) that mimic HMO functions -- can support a healthier gut microbiome in formula-fed infants at risk for colic. Synbiotic formulations combining L. reuteri with prebiotic substrates represent a promising avenue, though clinical trials are still limited.

Evidence Level: Preliminary

Future Directions

The understanding of infant colic as a microbiome-mediated condition has transformed both research and clinical practice. Several areas are advancing rapidly.

Precision microbiome profiling of newborns may soon allow clinicians to identify infants at high risk for colic before symptoms begin, based on early stool microbiome signatures. The observation that dysbiosis precedes crying onset by weeks^[2] supports the feasibility of this preventive approach.

Engineered synbiotics that combine specific L. reuteri strains with tailored prebiotic substrates could optimize colonization and efficacy in both breastfed and formula-fed infants. Next-generation infant formulas enriched with diverse HMO structures -- beyond the single HMO (2'-FL) currently available in some formulas -- may help close the microbiome gap between breastfed and formula-fed infants.

Maternal microbiome interventions during pregnancy and the postpartum period represent another frontier. Since breast milk bacteria originate partly from the maternal gut through an entero-mammary pathway, optimizing the mother's microbiome may improve the microbial seeding her infant receives.

Finally, understanding individual variation in treatment response remains important. Not all colicky infants respond equally to L. reuteri, and identifying biomarkers that predict probiotic responsiveness -- whether based on baseline microbiome composition, feeding mode, or inflammatory markers -- could guide personalized intervention strategies.

This content is for informational purposes only and does not constitute medical advice. Always consult a pediatrician or qualified healthcare provider before starting any probiotic or dietary intervention for an infant.